Transdermal selegiline: Targeted effects on monoamine oxidases in the brain

Biological Psychiatry

Volumn 54, Issue 10, 2003, Pages 1099-1104

  Wecker, Lynn ^a   James, Stephanie ^a   Copeland, Natalie ^a   Pacheco, Mary A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

"cheese" effect; Antidepressants; Brain selectivity; Depression; Gastrointestinal cells; Monoamine oxidases

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIDEPRESSANT AGENT; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL ABSORPTION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSDERMAL PATCH;

EID: 0242643659     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01892-9     Document Type: Article

References (19)

1. Anderson M.C., Hasan F., McCrodden J.M., Tipton K.F. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res. 18:1993;1145-1149.
2. Azzaro AJ, Blob LF, Kemper EM, Sharoky M, VanDenBerg CM (2000): Pressor effects of oral tyramine and over-the-counter (OTC) sympathomimetic amines following steady-state transdermal administration of selegiline to healthy volunteers. Presented at the American College of Neuropsychopharmacology (ACNP) 2000 Annual Meeting; December 13, 2000; San Juan, Puerto Rico.
3. Barrett J.S., Hochadel T.J., Morales R.J., Rohatagi S., DeWitt K.E., Watson S.K., et al. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am J Ther. 3:1996;688-698.
4. Berry M.D., Juorio A.V., Paterson I.A. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol. 44:1994;141-161.
5. Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet. 2:1963;849-851.
6. Blackwell B., Marley E., Price J., Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 113:1967;349-365.
7. Ekstedt B., Magyar K., Knoll J. Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? Biochem Pharmacol. 28:1979;919-923.
8. Elsworth J.D., Glover V., Reynolds G.P., Sandler M., Lees A.J., Phuapradit P., et al. Deprenyl administration in man A selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology. 57:1978;33-38.
9. Felner A.E., Waldmeier P.C. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol. 28:1979;995-1002.
10. Gareri P., Falconi U., DeFazio P., DeSarro G. Conventional and new antidepressant drugs in the elderly. Prog Neurobiol. 61:2000;353-396.
11. Gordon M.N., Muller C.D., Sherman K.A., Morgan D.G., Azzaro A.J., Wecker L. Oral versus transdermal selegiline Antidepressant-like activity in rats . Pharmacol Biochem Behav. 63:1999;501-506.
12. Hasan F., McCrodden J.M., Kennedy N.P., Tipton K.F. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Trans. 26:1988;1-9.
13. Kuhn W., Muller T. The clinical potential of Deprenyl in neurologic and psychiatric disorders. J Neural Trans. 48:1996;85-93.
14. Laux G. Do MAO-B inhibitors have any role in the treatment of depression? Szelenyi I. Inhibitors of Monoamine Oxidase B. 1993;319-326 Birkhauser Verlag, Basel, Switzerland.
15. Mann J.J., Aarons S.F., Wilner P.J., Keilp J.G., Sweeney J.A., Pearlstein T., et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 46:1989;45-50.
16. Mawhinney M, Cole D, Azzaro AJ (in press): Daily transdermal administration of selegiline preferentially inhibits monoamine oxidase activity in brain when compared to intestinal and hepatic tissues. J Pharm Pharmacol.
17. Rohatagi R., Barrett J.S., DeWitt K.E., Morales R.J. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos. 18:1997;567-584.
18. Strolin Benedetti M., Boucher T., Carlsson A., Fowler C.J. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem Pharmacol. 32:1983;47-52.
19. Strolin Benedetti M., Dostert P. Stereochemical aspects of MAO interactions Reversible and selective inhibitors of monoamine oxidase . Trends Pharmacol Sci. 6:1985;246-251.